Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hyaluronidase/Pembrolizumab - Merck

Next Previous
Drug Profile

Hyaluronidase/Pembrolizumab - Merck

Alternative Names: berahyaluronidase - Merck; KEYTRUDA QLEX; MK-3475/MK-5180; MK-3475A; MK-5180/MK-3475; Pembrolizumab + hyaluronidase subcutaneous - Merck; Pembrolizumab/Hyaluronidase - Merck; Pembrolizumab/MK-5180; Recombinant human hyaluronidase and pembrolizumab - Merck; Subcutaneous pembrolizumab - Merck

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Glycoside hydrolases; Immunotherapies; Monoclonal antibodies; Polysaccharide lyases; Small molecules; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Bladder cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase III Non-small cell lung cancer
  • Phase II Diffuse large B cell lymphoma; Hodgkin's disease; Malignant melanoma; Renal cell carcinoma; Squamous cell cancer

Most Recent Events

  • 11 Feb 2026 Registered for Fallopian tube cancer (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 11 Feb 2026 Registered for Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 11 Feb 2026 Registered for Peritoneal cancer (Combination therapy, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top